Access cutting-edge scleroderma treatment through this clinical trial at a research site in Ann Arbor. Study-provided care at no cost to qualified participants.
Access scleroderma specialists in Ann Arbor at no cost
This study follows strict safety protocols and ethical guidelines
All study-related scleroderma treatment provided free
The purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis relative to rituximab.
Sponsor: Novartis Pharmaceuticals
Check if you qualify for this scleroderma clinical trial in Ann Arbor, MI
If you're searching for scleroderma treatment options in Ann Arbor, MI, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Ann Arbor research site is actively enrolling participants for this clinical trial. You'll receive care from experienced scleroderma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.